Decreased sEng plasma levels in hypertensive patients with endothelial dysfunction under chronic treatment with Perindopril

References

• Blázquez-Medela AM, García-Ortiz L, Gómez-Marcos MA, et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med. 2010;8:86. doi:10.1186/1741-7015-8-8621171985
   PubMed Web of Science ®Google Scholar
• Rathouska J, Jezkova K, Nemeckova I, Nachtigal P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis. 2015;243(2):383–388. doi:10.1016/j.atherosclerosis.2015.10.00326520890
   PubMed Web of Science ®Google Scholar
• Davignon J. Cardioprotective and other emerging effects of statins. Int J Clin Pract Suppl. 2004;58(143):49–57.16035396
   PubMedGoogle Scholar
• Rakocevic J, Orlic D, Mitrovic-Ajtic O, et al. Endothelial cell markers from clinician‘s perspective. Exp Mol Pathol. 2017;102(2):303–313. doi:10.1016/j.yexmp.2017.02.00528192087
   PubMed Web of Science ®Google Scholar
• Blann AD, Wang JM, Wilson PB, Kumar S. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis. 1996;120(1–2):221–226.8645363
   PubMed Web of Science ®Google Scholar
• Botella LM, Sánchez-Elsner T, Sanz-Rodriguez F, et al. Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. Blood. 2002;100(12):4001–4010. doi:10.1182/blood.V100.12.400112433697
   PubMed Web of Science ®Google Scholar
• Miller DW, Graulich W, Karges B, et al. Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer. 1999;81(4):568–572.10225446
   PubMed Web of Science ®Google Scholar
• Perlingeiro RC. Endoglin is required for hemangioblast and early hematopoietic development. Development. 2007;134(16):3041–3048. doi:10.1242/dev.00290717634194
   PubMed Web of Science ®Google Scholar
• Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta. 2009;1792(10):954–973. doi:10.1016/j.bbadis.2009.07.00319607914
   PubMed Web of Science ®Google Scholar
• Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CP. Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis. 2000;153(2):323–335.11164421
   PubMed Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–649. doi:10.1038/nm142916751767
   PubMed Web of Science ®Google Scholar
• Levine RJ, Lam C, Qian C, et al.; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992–1005.16957146
   PubMed Web of Science ®Google Scholar
• Buda V, Andor M, Ledeti A, et al. Comparative solid-state stability of Perindopril active substance vs. pharmaceutical formulation. Int J Mol Sci. 2017;18(1):E164. doi:10.3390/ijms1801016428098840
   PubMed Web of Science ®Google Scholar
• Buda V, Andor M, Petrescu L, et al. Perindopril induces TSP-1 expression in hypertensive patients with endothelial dysfunction in chronic treatment. Int J Mol Sci. 2017;18(2):E348. doi:10.3390/ijms1802034828178210
   PubMed Web of Science ®Google Scholar
• Buda V, Andor M, Cristescu C, et al. The influence of perindopril on PTX3 plasma levels in hypertensive patients with endothelial dysfunction. Farmacia. 2016;64(3):382–389.
   Web of Science ®Google Scholar
• Kapur NK, Morine KJ, Letarte M. Endoglin: a critical mediator of cardiovascular health. Vasc Health Risk Manag. 2013;9:195–206. doi:10.2147/VHRM.S2914423662065
   PubMedGoogle Scholar
• Ikemoto T, Hojo Y, Kondo H, et al. Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels. 2012;27(4):344–351. doi:10.1007/s00380-011-0163-z21667051
   PubMed Web of Science ®Google Scholar
• Li CG, Bethell H, Wilson PB, Bhatnagar D, Walker MG, Kumar S. The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis. 2000;152(1):249–256.10996361
   PubMed Web of Science ®Google Scholar
• Casula M, Montecucco F, Bonaventura A, et al. Update on the role of pentraxin 3 in atherosclerosis and cardiovascular diseases. Vascul Pharmacol. 2017;99:1–12. doi:10.1016/j.vph.2017.10.00329051088
   PubMed Web of Science ®Google Scholar
• Torsney E, Charlton R, Parums D, Collis M, Arthur HM. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res. 2002;51(9):464–470.12365720
   PubMed Web of Science ®Google Scholar
• Kapur NK, Heffernan KS, Yunis AA, et al. Usefulness of soluble endoglin as a noninvasive measure of left ventricular filling pressure in heart failure. Am J Cardiol. 2010;106(12):1770–1776. doi:10.1016/j.amjcard.2010.08.01821126621
   PubMed Web of Science ®Google Scholar
• Kapur NK, Wilson S, Yunis AA, et al. Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation. 2012;125(22):2728–2738. doi:10.1161/CIRCULATIONAHA.111.08000222592898
   PubMed Web of Science ®Google Scholar
• Prieto M, Rodríguez-Peña A, Arévalo M, et al. Effect of the long-term treatment with trandolapril on endoglin expression in rats with experimental renal fibrosis induced by renal mass reduction. Kidney Blood Press Res. 2005;28(1):32–40. doi:10.1159/00008143915475654
   PubMed Web of Science ®Google Scholar
• Rathouska J, Vecerova L, Strasky Z, et al. Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacol Res. 2011;64(1):53–59. doi:10.1016/j.phrs.2011.03.00821440631
   PubMed Web of Science ®Google Scholar